Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$47.79 USD
-3.30 (-6.46%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $47.71 -0.08 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRAX 47.79 -3.30(-6.46%)
Will PRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRAX
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ensign Group (ENSG) Q4 Earnings and Revenues Beat Estimates
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Other News for PRAX
Praxis Precision Medicine (PRAX): HC Wainwright & Co. Raises Price Target | PRAX Stock News
PRAX Price Target Increased by H.C. Wainwright Following Positive Trial Results
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News
Praxis Precision price target raised by $10 at H.C. Wainwright, here's why
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ...